Clinical Outcomes and Quality of Life after Patent Foramen Ovale (PFO) Closure in Patients with Stroke/Transient Ischemic Attack of Undetermined Cause and Other PFO-Associated Clinical Conditions: A Single-Center Experience

Introduction: The aim of this study was to assess clinical outcomes and quality of life after PFO closure in patients with previous stroke/TIA of undetermined cause and in patients with other complex PFO-associated clinical conditions. Methods: Between July 2009 and December 2019 at our University Cardiology Department, 118 consecutive patients underwent a thorough diagnostic work-up including standardized history taking, clinical evaluation, full neurological examination, screening for thrombophilia, brain magnetic resonance imaging (MRI), ultrasound–Doppler sonography of supra-aortic vessels and 24 h ECG Holter monitoring. Anatomo-morphological evaluation using 2D transthoracic/transesophageal echocardiography (TTE/TEE) color Doppler and functional assessment using contrast TTE (cTTE) in the apical four-chamber view and contrast transcranial Doppler (cTCD) using power M-mode modality were performed to verify the presence, location and amount of right-to-left shunting via PFO or other extracardiac source. Completed questionnaires based on the Quality-of-Life Short Form-36 (QoL SF-36) and Migraine Disability Assessment (MIDAS) were obtained from the patients before PFO closure and after 12 months. Contrast TTE/TEE and cTCD were performed at dismission, 1, 6 and 12 months and yearly thereafter. Brain MRI was performed at 1-year follow-up in 54 patients. Results: Transcatheter PFO closure was performed in 106 selected symptomatic patients (mean age 41.7 ± 10.7 years, range 16–63, 65% women) with the following conditions: ischemic stroke (n = 23), transient ischemic attack (n = 22), peripheral and coronary embolism (n = 2), MRI lesions without cerebrovascular clinical events (n = 53), platypnea–orthodeoxia (n = 1), decompression sickness (n = 1) and refractory migraine without ischemic cerebral lesions (n = 4). The implanted devices were Occlutech Figulla Flex I/II PFO (n = 99), Occlutech UNI (n = 3), Amplatzer PFO (n = 3) and CeraFlex PFO occluders (n = 1). Procedures were performed under local anesthesia and rotational intracardiac monitoring (Ultra ICE) alone. The devices were correctly implanted in all patients. The mean fluoroscopy time was 15 ± 5 min (range = 10–45 min) and the mean procedural time was 55 ± 20 min (range = 35–90 min). The total occlusion rate at follow-up (mean 50 months, range 3–100) was 98.1%. No recurrent neurological events were observed in the long-term follow-up. Conclusions: The data collected in this study demonstrate that percutaneous PFO closure is a safe and effective procedure, showing long-term prevention of recurrent cerebrovascular events, significant reduction in migraine symptoms and substantial improvement in quality of life.

[1]  Lin Li,et al.  Pitfalls of Using Imaging Technique in the Presence of Eustachian Valve or Chiari Network: Effects on Right-to-Left Shunt and Related Influencing Factors , 2022, Diagnostics.

[2]  A. Schwarz,et al.  Obstructive Sleep Apnea (OSA) and Patent Foramen Ovale (PFO), the “Perfect Storm” for a Cryptogenic Stroke? Case Series of Four Patients , 2022, Frontiers in Stroke.

[3]  Andrew J. Sims,et al.  Patent foramen ovale closure: A prospective UK registry linked to hospital episode statistics , 2022, PloS one.

[4]  Shota Saito,et al.  Cost-effectiveness analysis of patent foramen ovale closure versus medical therapy alone after cryptogenic stroke , 2022, PloS one.

[5]  Yajuan Du,et al.  A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder , 2022, Frontiers in Cardiovascular Medicine.

[6]  J. Carroll,et al.  SCAI Guidelines for the Management of Patent Foramen Ovale , 2022, Journal of the Society for Cardiovascular Angiography & Interventions.

[7]  Yu Cao,et al.  Platelet P2Y12 Inhibitor in the Treatment and Prevention of Migraine: A Systematic Review and Meta-Analysis , 2022, Behavioural neurology.

[8]  S. Malaisrie,et al.  Chiari network and patent foramen ovale associated with stroke , 2021, JTCVS techniques.

[9]  P. Germonpré,et al.  Increased Risk of Decompression Sickness When Diving With a Right-to-Left Shunt: Results of a Prospective Single-Blinded Observational Study (The “Carotid Doppler” Study) , 2021, Frontiers in Physiology.

[10]  E. Onorato Large eustachian valve fostering paradoxical thromboembolism: passive bystander or serial partner in crime? , 2021, World journal of cardiology.

[11]  H. Kamel,et al.  2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. , 2021, Stroke.

[12]  J. Carroll,et al.  European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. , 2021, European heart journal.

[13]  Sabawoon Mirwais,et al.  Patent Foramen Ovale With Platypnea – Orthodeoxia Syndrome: A Case Report , 2020, Cureus.

[14]  A. Anselmi Commentary: Patent foramen ovale is not always a benign condition , 2020, JTCVS techniques.

[15]  C. Johnson,et al.  Burden of Stroke in Europe , 2020, Stroke.

[16]  P. Mitsias,et al.  Patent Foramen Ovale in Cryptogenic Ischemic Stroke: Direct Cause, Risk Factor, or Incidental Finding? , 2020, Frontiers in Neurology.

[17]  J. Carroll,et al.  Practice advisory update summary: Patent foramen ovale and secondary stroke prevention , 2020, Neurology.

[18]  P. Calvert,et al.  Patent Foramen Ovale Closure: State of the Art , 2020, Interventional cardiology.

[19]  É. Marijon,et al.  Reprint of : Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology. , 2019, Revue neurologique.

[20]  S. Kasner,et al.  Cost-effectiveness of percutaneous closure of a patent foramen ovale compared with medical management in patients with a cryptogenic stroke: from the US payer perspective , 2019, Journal of medical economics.

[21]  T. Villines,et al.  Cost effectiveness and clinical efficacy of patent foramen ovale closure as compared to medical therapy in cryptogenic stroke patients: A detailed cost analysis and meta-analysis of randomized controlled trials. , 2018, International journal of cardiology.

[22]  S. Kasner,et al.  Evaluating the cost-effectiveness of percutaneous closure of a patent foramen ovale versus medical management in patients with a cryptogenic stroke: from the UK payer perspective , 2018, Journal of medical economics.

[23]  T. Nazif,et al.  Retrospective review of thienopyridine therapy in migraineurs with patent foramen ovale , 2018, Neurology.

[24]  B. Meier,et al.  European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. , 2018, European heart journal.

[25]  Ayman Elbadawi,et al.  Meta-analysis of randomized trials on percutaneous patent foramen ovale closure for prevention of migraine , 2018, Acta cardiologica.

[26]  G. Chatellier,et al.  Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta‐Analysis, and New Insights From the CLOSE Study , 2018, Journal of the American Heart Association.

[27]  G. Sgueglia,et al.  Novel percutaneous suture-mediated patent foramen ovale closure technique: early results of the NobleStitch EL Italian Registry. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[28]  J. Carroll,et al.  Cost-Effectiveness of Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Stroke Prevention , 2018, Stroke.

[29]  Seung‐Jung Park,et al.  Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. , 2018, Journal of the American College of Cardiology.

[30]  M. Dellborg,et al.  Quality of life after percutaneous closure of patent foramen ovale in patients after cryptogenic stroke compared to a normative sample. , 2018, International journal of cardiology.

[31]  J. Carroll,et al.  Cost-effectiveness of percutaneous patent foramen ovale closure as secondary stroke prevention , 2018, Journal of medical economics.

[32]  D. Holmes,et al.  Coronary Embolus: An Underappreciated Cause of Acute Coronary Syndromes. , 2018, JACC. Cardiovascular interventions.

[33]  S. Silberstein,et al.  Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial. , 2017, Journal of the American College of Cardiology.

[34]  Helle K. Iversen,et al.  Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke , 2017, The New England journal of medicine.

[35]  David E. Thaler,et al.  Long‐Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke , 2017, The New England journal of medicine.

[36]  S. Qureshi,et al.  Interventions in Structural, Valvular and Congenital Heart Disease , 2015 .

[37]  E. Loder,et al.  The Prevalence and Burden of Migraine and Severe Headache in the United States: Updated Statistics From Government Health Surveillance Studies , 2015, Headache.

[38]  M. Roffi,et al.  Platypnea-orthodeoxia syndrome in the elderly treated by percutaneous patent foramen ovale closure: a case series and literature review. , 2013, European journal of internal medicine.

[39]  D. Kent,et al.  An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke , 2013, Neurology.

[40]  Elizabeth Loder,et al.  The Prevalence, Impact, and Treatment of Migraine and Severe Headaches in the United States: A Review of Statistics From National Surveillance Studies , 2013, Headache.

[41]  R. Sterzi,et al.  Wake-up stroke and TIA due to paradoxical embolism during long obstructive sleep apnoeas: a cross-sectional study , 2012, Thorax.

[42]  E. Parati,et al.  Microembolic Air Load During Contrast‐Transcranial Doppler: A Trigger for Migraine With Aura? , 2010, Headache.

[43]  J. Ioannidis,et al.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.

[44]  D. Dodick,et al.  Patent Foramen Ovale and Migraine: A Quantitative Systematic Review , 2008, Cephalalgia : an international journal of headache.

[45]  A. Dowson,et al.  Migraine Intervention With STARFlex Technology (MIST) Trial: A Prospective, Multicenter, Double-Blind, Sham-Controlled Trial to Evaluate the Effectiveness of Patent Foramen Ovale Closure With STARFlex Septal Repair Implant to Resolve Refractory Migraine Headache , 2008, Circulation.

[46]  Peter Wilmshurst,et al.  The Role of Cardiac and Pulmonary Pathology in Migraine: A Hypothesis , 2006, Headache.

[47]  R. Virmani,et al.  Patent foramen ovale: current pathology, pathophysiology, and clinical status. , 2005, Journal of the American College of Cardiology.

[48]  A. Angelini,et al.  Intracardiac echocardiography: gross anatomy and magnetic resonance correlations and validations , 2005, The International Journal of Cardiovascular Imaging.

[49]  Robert H. Anderson,et al.  Development of the heart: (2) Septation of the atriums and ventricles , 2003, Heart.

[50]  P. Wilmshurst,et al.  Relationship between migraine and cardiac and pulmonary right-to-left shunts. , 2001, Clinical science.

[51]  E. Zanette,et al.  Detection of Right-to-Left Shunt with Ultrasound Contrast Agent and Transcranial Doppler Sonography , 2000, Cerebrovascular Diseases.

[52]  F. Chédru,et al.  Atrial Septal Aneurysm and Patent Foramen Ovale as Risk Factors for Cryptogenic Stroke in Patients Less Than 55 Years of Age: A Study Using Transesophageal Echocardiography , 1993, Stroke.

[53]  J. Newburger,et al.  Transcatheter Closure of Patent Foramen Ovale After Presumed Paradoxical Embolism , 1992, Circulation.